Apogee Therapeutics said its Phase 2 APEX Part A study of zumilokibart delivered 52-week maintenance data showing durable response in moderate-to-severe atopic dermatitis, with the strongest figures tied to less frequent dosing.
Among patients who responded by week 16, 75% of those on every-3-month dosing maintained EASI-75 at week 52, while 85% did so on every-6-month dosing. VIGA 0/1 maintenance was 86% with 3-month dosing and 78% with 6-month dosing.
The company also said responses deepened over time across all lesion and itch measures in the full treated population, not just the week 16 responders. The 52-week data were based on 360 mg maintenance dosing.
Safety over the year was described as generally consistent with the class. The most common treatment-emergent adverse events were noninfective conjunctivitis, upper respiratory tract infection and nasopharyngitis.
Apogee said APEX Part B, a placebo-controlled dose-optimization study in 347 patients, is set to produce 16-week data in the second quarter of 2026. The company expects to start Phase 3 trials in the second half of 2026, after which it is targeting a potential 2029 launch.
The company also highlighted the dosing gap versus current therapies, saying zumilokibart could be administered as few as two times per year, compared with up to 26 injections annually for existing options. Today the company's shares have moved 0.03% to a price of $80.77. If you want to know more, read the company's complete 8-K report here.
